istock-1030818812_artisteer

artisteer / iStockphoto.com

22 October 2018Biotechnology

Gene-editing: a block on further development

In late July, Europe’s highest court handed down a much-awaited ruling on gene-editing which was met by an uproar from parts of the scientific community.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

Does the UPC offer a fresh take on patent validity?

Litigation implications of the USPTO’s terminal disclaimer proposal

Ipsen files further suit against CSPC over pancreatic cancer drug generic

Federal Circuit denies rehearing in heart valve case

Technical prejudice in support of inventive step: A double-edged sword?